Search Results - cancer+therapeutics

5 Results Sort By:
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...
Published: 10/28/2024   |   Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney
Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Benzylthiophene Derivatives
 
Published: 6/17/2022   |   Inventor(s): Lawrence Pfeffer, Yinan Wang, Chuan Yang
Keywords(s): Cancer, Cancer therapeutics, Oncology
Category(s): Human Health
Bromodomaine Inhibitors to Target Therapy-Resistant Cancer
The Problem:Glioblastoma multiforme (GBM) is the most common and the most aggressive malignant brain tumor in adults, having an overall incidence of approximately three new cases per 100,000 persons per year. Presently, GBM is highly lethal, with a median survival of 14 to15 months after diagnosis and no effective treatment for a significant long-term...
Published: 4/27/2022   |   Inventor(s): Duane Miller, Lawrence Pfeffer, Yali He, Debolina Ganguly
Keywords(s): Cancer, Cancer therapeutics, Therapeutics
Category(s): Human Health
N-Heterocyclic Carbene Aptamers that Target Drug Delivery to Specific Cancer Cells
Cytotoxic Therapy Targets Malignancies, Avoiding Healthy Cells and Negative Side Effects Caused by Heavy Metal Buildup in OrgansThese aptamers, conjugated with N-heterocyclic carbene metal complexes, deliver therapeutic doses of the cytotoxic metal ion to targeted cancer cells. These complexes avoid toxicity to healthy cells while being highly effective...
Published: 6/27/2021   |   Inventor(s): Adam Veige, Mary Garner, Weijia Niu
Keywords(s): Aptamer crosslinker, aptamers, Cancer Cells Targeting, Cancer Drug Delivery, Cancer Drugs, Cancer Therapeutics, Cancer Therapeutics: Small Molecule, carbene, Cytotoxic, metal ion
Category(s): Technology Classifications > Engineering > Chemical, Technology Classifications > Human Health Care > Therapeutics
Small Molecule Inhibitors of Autotaxin for Cancer Therapeutics
Technical Field:Cancer invasion and metastasis, lymphocyte recirculation, macular angiogenesis, allodynia and neuropathic pain, inflammation, cholestasis-associated pruritus.The Technology: Autotaxin (ATX, NPP2) is a member of the nucleotide pyrophosphate phosphodiesterase enzyme family. ATX catalyzes the hydrolytic cleavage of lysophosphatidylcholine...
Published: 11/7/2024   |   Inventor(s): Duane Miller, Gabor Tigyi, Renuka Gupte, Renukadevi Patil
Keywords(s): Autotaxin, Cancer, Cancer therapeutics, Oncology, Small molecule
Category(s): Human Health